523 related articles for article (PubMed ID: 28824858)
1. Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.
Chen L; Ilham SJ; Feng B
Anesth Pain Med; 2017 Apr; 7(2):e42747. PubMed ID: 28824858
[TBL] [Abstract][Full Text] [Related]
2. Treatment of irritable bowel syndrome.
Trinkley KE; Nahata MC
J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
[TBL] [Abstract][Full Text] [Related]
3. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
Farthing MJ
Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
[TBL] [Abstract][Full Text] [Related]
4. Novel pharmacological therapies for irritable bowel syndrome.
Corsetti M; Whorwell P
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):807-15. PubMed ID: 26907518
[TBL] [Abstract][Full Text] [Related]
5. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
[TBL] [Abstract][Full Text] [Related]
6. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
7. How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome.
Vahora IS; Tsouklidis N; Kumar R; Soni R; Khan S
Cureus; 2020 Aug; 12(8):e9871. PubMed ID: 32968548
[TBL] [Abstract][Full Text] [Related]
8. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
Scarpellini E; Laterza L; Ianiro G; Tack J; Abenavoli L; Gasbarrini A
Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
[TBL] [Abstract][Full Text] [Related]
9. Dietary and pharmacological treatment of abdominal pain in IBS.
Camilleri M; Boeckxstaens G
Gut; 2017 May; 66(5):966-974. PubMed ID: 28232472
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.
Mozaffari S; Nikfar S; Abdollahi M
Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):403-21. PubMed ID: 23330973
[TBL] [Abstract][Full Text] [Related]
11. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments.
Farzaei MH; Bahramsoltani R; Abdollahi M; Rahimi R
J Neurogastroenterol Motil; 2016 Oct; 22(4):558-574. PubMed ID: 27431236
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
13. Current gut-directed therapies for irritable bowel syndrome.
Chang HY; Kelly EC; Lembo AJ
Curr Treat Options Gastroenterol; 2006 Jul; 9(4):314-23. PubMed ID: 16836950
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
15. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
16. Update on Pharmacotherapy for Irritable Bowel Syndrome.
Munjal A; Dedania B; Cash B
Curr Gastroenterol Rep; 2019 Apr; 21(6):25. PubMed ID: 31025114
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
18. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
19. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome.
Mousavi T; Nikfar S; Abdollahi M
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):583-604. PubMed ID: 32380874
[TBL] [Abstract][Full Text] [Related]
20. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
